Dicerna Pharmaceuticals (DRNA) Rating Lowered to Neutral at HC Wainwright

HC Wainwright downgraded shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a buy rating to a neutral rating in a research report released on Friday, MarketBeat Ratings reports. HC Wainwright currently has $12.00 price target on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. BidaskClub downgraded shares of Dicerna Pharmaceuticals from a strong-buy rating to a buy rating in a report on Wednesday, March 21st. Chardan Capital assumed coverage on shares of Dicerna Pharmaceuticals in a report on Friday, March 9th. They issued a neutral rating on the stock. Stifel Nicolaus lifted their price objective on shares of Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the company a buy rating in a report on Friday, March 9th. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a hold rating to a sell rating in a report on Friday, February 9th. Finally, SunTrust Banks assumed coverage on shares of Dicerna Pharmaceuticals in a report on Monday, February 5th. They issued a buy rating and a $13.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $11.54.

How to Become a New Pot Stock Millionaire

Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) opened at $10.99 on Friday. Dicerna Pharmaceuticals has a fifty-two week low of $2.52 and a fifty-two week high of $15.00.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.25). Dicerna Pharmaceuticals had a negative net margin of 2,637.15% and a negative return on equity of 171.81%. The business had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.45 million. The company’s revenue was up 976.9% compared to the same quarter last year. analysts forecast that Dicerna Pharmaceuticals will post -1.97 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Endurant Capital Management LP bought a new position in shares of Dicerna Pharmaceuticals in the fourth quarter valued at $170,000. Emerald Advisers Inc. PA bought a new position in shares of Dicerna Pharmaceuticals in the fourth quarter valued at $266,000. Northern Trust Corp grew its stake in shares of Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 2,094 shares in the last quarter. EAM Investors LLC bought a new position in shares of Dicerna Pharmaceuticals in the fourth quarter valued at $581,000. Finally, Millennium Management LLC grew its stake in shares of Dicerna Pharmaceuticals by 142.8% in the fourth quarter. Millennium Management LLC now owns 66,907 shares of the biopharmaceutical company’s stock valued at $604,000 after buying an additional 39,348 shares in the last quarter. 75.28% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Dicerna Pharmaceuticals (DRNA) Rating Lowered to Neutral at HC Wainwright” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3302124/dicerna-pharmaceuticals-drna-rating-lowered-to-neutral-at-hc-wainwright.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Q3 2018 EPS Estimates for Stelco Holdings Inc.  Increased by Analyst
Q3 2018 EPS Estimates for Stelco Holdings Inc. Increased by Analyst
SolarCoin One Day Volume Reaches $78,113.00
SolarCoin One Day Volume Reaches $78,113.00
Eroscoin Price Tops $0.0411 on Top Exchanges
Eroscoin Price Tops $0.0411 on Top Exchanges
Paratek Pharmaceuticals  Downgraded to “Strong Sell” at BidaskClub
Paratek Pharmaceuticals Downgraded to “Strong Sell” at BidaskClub
Nicolet Bankshares  Upgraded to “Hold” at BidaskClub
Nicolet Bankshares Upgraded to “Hold” at BidaskClub
51job  Lowered to Buy at BidaskClub
51job Lowered to Buy at BidaskClub


© 2006-2018 Ticker Report. Google+.